A Phase I Open-Label Safety Study of Escalating Doses of Taxotere [docetaxel] in Combination With Escalating Doses of GEM231 in Patients With Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2017
At a glance
- Drugs Docetaxel (Primary) ; GEM 231 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Dec 2011 Actual patient number 6 added as reported by ClinicalTrials.gov.
- 31 Dec 2011 Additional lead trial centre (Montefiore Medical Center) identified as reported by ClinicalTrials.gov.
- 10 Jul 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.